Closing Remarks
January 29, 2016
Cervix Cancer Education Symposium, January 2017, Mexico City
<table>
<thead>
<tr>
<th>Cancer Type</th>
<th>Radiotherapy Utilisation Rate (%)</th>
<th>Mean Radiotherapy Fractions per Course</th>
<th>5-Year Local Control Benefit (%)</th>
<th>5-Year Overall Survival Benefit (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>87</td>
<td>16</td>
<td>15</td>
<td>2</td>
</tr>
<tr>
<td>Cervix</td>
<td>71</td>
<td>21</td>
<td>35</td>
<td>20</td>
</tr>
<tr>
<td>Colorectal</td>
<td>19</td>
<td>23</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Haematological</td>
<td>48</td>
<td>8</td>
<td>7</td>
<td>4</td>
</tr>
<tr>
<td>Head and Neck</td>
<td>74</td>
<td>22</td>
<td>34</td>
<td>20</td>
</tr>
<tr>
<td>Liver</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Lung</td>
<td>77</td>
<td>16</td>
<td>9</td>
<td>6</td>
</tr>
<tr>
<td>Oesophagus</td>
<td>71</td>
<td>15</td>
<td>5</td>
<td>2</td>
</tr>
<tr>
<td>Prostate</td>
<td>58</td>
<td>28</td>
<td>25*</td>
<td>1</td>
</tr>
<tr>
<td>Stomach</td>
<td>27</td>
<td>19</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>18</td>
<td>10</td>
<td>4</td>
</tr>
</tbody>
</table>

Radiotherapy utilisation rate is the number of patients for whom radiotherapy is the treatment of choice according to guidelines and evidence, divided by the number of new cases in one year. Haematological cancers include leukaemia, Hodgkin’s lymphoma, non-Hodgkin lymphoma, and multiple myeloma. *5-year biochemical disease-free survival for curative cases only.

Table 1: Radiotherapy utilisation rate, mean fractions, and outcome benefits (absolute proportional) for top ten cancers globally by incidence.
CCRN: Significant Issues

- Money (Funding Sources)
- Per case reimbursement?
- Accrual
- Ongoing oversight (QA and FU)
- Insurance/Indemnity issues
- Site Selection
- Infrastructure (clinical trials management)
CCRN: Current Support

• Funding Sources (on going)
  • IGCS
  • GCIG

• This meeting supported by:
  • Elekta
  • Varian
  • Advaxis
  • Stendahl
  • Zeria
CCRN: Potential Sources of Support

- IGCS (current support)
- GCIG (current support)
- Center for Global Health, NIH, USA
- Gates Foundation and other Foundations
- ASCO grants
- Industry (Elekta/Varian/Pharma)
- CCRN Society (Dues)
- Grants (eg ASCO and others)
- Charitable Organizations
- Social Media
- Advocacy Groups
CCRN: Thanks!

• Our Hosts

• Funding for this meeting
  • Elekta
  • Varian
  • Advaxis
  • Stendahl
  • Zeria

• Funding for CCRN
  • GCIG
  • IGCS

• All of you

• And, Monica, of course!